Studies have confirmed that the ORR of PD-1/PD-L1 inhibitor monotherapy was less than 20% in patients with advanced HCC (24), suggesting that the effect of monotherapy in HCC patients was very limited, and more effective treatment options needed to be explored. The gene discussed is CD274; the disease is hepatocellular carcinoma.